Cardiovascular Center and Department of Anesthesiology, Taichung Veterans General Hospital, Taichung, Taiwan.
Eur J Pharmacol. 2010 Oct 10;644(1-3):176-87. doi: 10.1016/j.ejphar.2010.07.010. Epub 2010 Jul 23.
Cardiac toxicity remains a serious yet unsolved complication of doxorubicin. This study was designed to examine whether doxycycline, a tetracycline-derived synthetic antibiotic with potential cytoprotective properties, could ameliorate this complication of doxorubicin. Male mice at 4-week of age were administrated with vehicle, doxorubicin (3mg/kg intraperitoneally every other day at 3 doses), doxycycline (2.5mg/kg intraperitoneally every other day for 3 doses), or doxycycline plus doxorubicin (each dose given 1day post doxycycline). After 28days, left ventricular geometric and systolic parameters were measured by transthoracic echocardiography, and hearts were harvested for extensive analyses regarding oxidative stress and cellular apoptosis. At 28days, hearts of doxorubicin-treated mice were characterized by less weight compared with controls, also with remodeling and depressed systolic function of the left ventricle. Biochemical analyses disclosed that content of malondialdehyde was increased and activity of antioxidant enzymes, including superoxide dismutase and glutathione peroxidase, was decreased in these hearts. Both mitochondrion-dependent and endoplasmic reticulum stress-induced apoptotic pathways were also activated in the hearts of doxorubicin-treated mice as reflected by decreased Bcl-2/Bcl-(XL) and elevated Bax/Bad, p53/Apaf-1, endoplasmic reticulum glucose-related protein 78, C/EBP homologous protein, cytochrome c release from mitochondria, caspases-9/-3 cleavage, and cardiomyocyte apoptosis. In contrast, all the above left ventricular remodeling, systolic depressing, oxidative and pro-apoptotic actions of doxorubicin could be significantly alleviated by doxycycline pretreatment. Thus, doxycycline extensively counteracts multiple oxidative and apoptotic actions of doxorubicin in heart, hence may serve as an adjuvant agent to assuage the untoward cardiac effects of doxorubicin in clinical application.
阿霉素的心脏毒性仍然是一个严重但尚未解决的并发症。本研究旨在探讨多西环素(一种具有潜在细胞保护作用的四环素衍生合成抗生素)是否可以改善阿霉素的这种并发症。4 周龄雄性小鼠接受 vehicle、阿霉素(3mg/kg,每 2 天腹腔注射 1 次,共 3 次)、多西环素(2.5mg/kg,每 2 天腹腔注射 1 次,共 3 次)或多西环素加阿霉素(每次剂量在多西环素给药后 1 天给予)。28 天后,通过经胸超声心动图测量左心室几何形状和收缩参数,并采集心脏进行广泛的氧化应激和细胞凋亡分析。28 天后,与对照组相比,阿霉素处理的小鼠心脏的重量减轻,左心室重构和收缩功能降低。生化分析显示,这些心脏中的丙二醛含量增加,抗氧化酶(包括超氧化物歧化酶和谷胱甘肽过氧化物酶)的活性降低。阿霉素处理的小鼠心脏中还激活了线粒体依赖性和内质网应激诱导的凋亡途径,反映为 Bcl-2/Bcl-(XL) 减少和 Bax/Bad、p53/Apaf-1、内质网葡萄糖相关蛋白 78、C/EBP 同源蛋白、细胞色素 c 从线粒体释放、caspase-9/-3 切割和心肌细胞凋亡增加。相比之下,多西环素预处理可显著减轻阿霉素引起的所有上述左心室重构、收缩抑制、氧化和促凋亡作用。因此,多西环素广泛对抗阿霉素在心脏中的多种氧化和凋亡作用,因此可能作为一种辅助剂在临床应用中减轻阿霉素的不良心脏作用。